Jove
Visualize
联系我们

相关概念视频

Tumor Progression02:07

Tumor Progression

7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mitral Valve Repair vs. Replacement: Hemodynamics in Valve Surgery.

Reviews in cardiovascular medicine·2026
Same author

Prognostic nutritional index and long-term outcomes after coronary artery bypass grafting.

BMC surgery·2026
Same author

Gene-Lifestyle Interplay in Type 1 Diabetes: Joint Effects and Interactions From Cross-Sectional and Longitudinal Cohort Analyses.

Diabetes/metabolism research and reviews·2026
Same author

Integrative genomic profiling of iron homeostasis predicts clinical outcomes and identifies HAMP/hepcidin as a therapeutic target in colorectal cancer.

Cell & bioscience·2026
Same author

Integrated intraocular-plasma proteomics reveals conserved biomarkers for diabetic retinopathy progression: a multi-fluid biopsy study.

Diabetologia·2026
Same author

Correction: Xu et al. Notch1 Protects Against Ischemic-Reperfusion Injury by Suppressing PTEN-Pink1-Mediated Mitochondrial Dysfunction and Mitophagy. <i>Cells</i> 2023, <i>12</i>, 137.

Cells·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 12, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K

在骨髓瘤中,炎症驱动的预后模型和免疫景观概况.

Rongquan Zhang1, Xueliang Zhou1, Chenxiao Shen2

  • 1Zhejiang Province People's Hospital Haining Hospital, Jiaxing, China.

Discover oncology
|November 7, 2025
PubMed
概括

一个新的11基因签名通过分析炎症来预测骨髓瘤患者的生存率. 这种与炎症相关的风险模型提供了一个预后工具,并建议治疗目标,包括Temozolomide的潜在重新用途.

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 生物信息学是一种生物信息学.

背景情况:

  • 骨髓瘤 (OS) 是年轻成年人的主要骨癌,预后不佳,特别是在转移性病例中.
  • 瘤微环境中的慢性炎症驱动OS进展和免疫逃避.
  • 现有的预后模型往往缺乏与炎症相关的分子特征.

研究的目的:

  • 基于与炎症相关的基因,开发一种新的骨髓瘤预后模型.
  • 研究瘤炎症,免疫透和患者存活率之间的关系.
  • 为了确定潜在的治疗目标和药物重新利用的机会,OS.

主要方法:

  • 利用TCGA对骨髓瘤患者的大量RNA-seq数据.
  • 定义了一个炎症基因组,并使用LASSO和Cox回归来确定预后基因.
  • 构建并验证了一个11个基因风险评分模型和一个名图.
  • 分析了单细胞RNA-seq数据,以在细胞类型中映射炎症基因表达.
  • 评估了免疫透,并进行了途径丰富分析.

主要成果:

  • 根据11个基因的特征,患者被分为高风险和低风险组,总体存活率显著不同 (p < 0.001).
关键词:
免疫系统的透.与炎症相关的基因骨质肉瘤骨质肉瘤是什么风险评分模型的风险评分模型.单细胞RNA测序的一个细胞.

更多相关视频

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.2K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K

相关实验视频

Last Updated: Jan 12, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.2K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K
  • 预后模型实现了高分辨能力 (AUC 0.808-0.879在1-5年).
  • 单细胞分析显示了特定的免疫细胞丰富,低风险瘤显示了更高的免疫透和活性.
  • 分子对接建议Temozolomide作为潜在的药物重新定位候选人,针对TERT.

    • 结论:

    • 开发了一种新的,基于炎症的骨髓瘤预后工具.
    • 阐明了OS中瘤炎症和免疫微环境之间的复杂相互作用.
    • 确定了潜在的治疗策略和药物重定向候选人用于骨髓瘤治疗.